Company Filing History:
Years Active: 2013
Title: Innovator Elisabeth C. M. Brinkman: Pioneering Advances in Medicine
Introduction: Elisabeth C. M. Brinkman, based in Noordwijkerbout, Netherlands, is an esteemed inventor recognized for her significant contributions to medical science. With a focus on therapeutic innovations, she has developed key inventions that aim to improve healthcare outcomes for patients with specific genetic deficiencies.
Latest Patents: Brinkman holds one notable patent for "Recombinant human Alpha1-antitrypsin," which presents innovative features such as recombinant human α1-antitrypsin (rhAAT) that includes N-linked glycans. In her invention, at least 10% of said N-linked glycans are tetra-antennary glycans, and the degree of capping with sialic acid on these glycans is a minimum of 50%. This invention is particularly relevant for its application as a medicament, particularly in preventing and/or treating diseases associated with AAT (Alpha-1 Antitrypsin) deficiency and conditions involving neutrophil-mediated tissue damage.
Career Highlights: Elisabeth has dedicated her professional career to advancing therapeutic modalities through her innovative inventions. Working at Crucell Holland B.V., she has contributed significantly to the field of biopharmaceuticals, focusing on the development of proteins for therapeutic use. Her expertise and creativity enable her to address unmet medical needs effectively.
Collaborations: Throughout her career, Elisabeth has collaborated with notable colleagues such as Cornelis Erik Hack and Ingrid Van Den Nieuwenhof. These collaborations have enhanced her research capabilities and have led to impactful strides in the field of medical innovation.
Conclusion: Elisabeth C. M. Brinkman stands out as a remarkable inventor whose contributions to recombinant human Alpha1-antitrypsin exemplify a commitment to improving health outcomes. With her innovative spirit and collaborative approach, she continues to drive advancements in therapeutic sciences that hold promise for patients worldwide.